A detailed history of Silvercrest Asset Management Group LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 103,500 shares of ALT stock, worth $898,380. This represents 0.0% of its overall portfolio holdings.

Number of Shares
103,500
Previous 103,500 -0.0%
Holding current value
$898,380
Previous $688,000 7.7%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $611,685 - $1.06 Million
-103,500 Reduced 50.0%
103,500 $688,000
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $611,685 - $1.06 Million
103,500 Added 100.0%
207,000 $1.38 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $171,790 - $690,029
41,000 Added 65.6%
103,500 $436,000
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $368,750 - $590,625
62,500 New
62,500 $381,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $426M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Silvercrest Asset Management Group LLC Portfolio

Follow Silvercrest Asset Management Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.